The clopidogrel therapy in clinical trials

Abstract

The guidelines concerning treatment of acute coronary syndromes (ACS) resist mainly on results of big clinical research, evaluating influence individual therapeutic method on clinically importantend-points (risk of death, heart infarct, ischemic return). Big percentage of incident of secondary closure of vessel after efficient reperfusion present substantiation for feeding antiplatelet medications in acute phase of ST elevation myocardial infarction. These medications belong to one of the most important group in modern pharmacotherapy. According to current guideliness of European Society of Cardiology, preferred oral antiplatelet medications, inhibitors of antiplatelet receptor P2Y12 in patients with ACS are prasugrel and ticagrelor. However in many countries clopidogrel is still most often applied medication from this group.